Paul Tapang

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose, Joel D. Leverson, Franklin Peale et al. · Molecular Cancer Therapeutics · 2016 · 309 citations

Medicine, Pharmacology, Chemotherapy +11

Discovery of<i>N</i>-(4-(3-Amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

Yujia Dai, Kresna Hartandi, Zhiqin Ji et al. · Journal of Medicinal Chemistry · 2007 · 185 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

Yujia Dai, Yan Guo, Robin R. Frey et al. · Journal of Medicinal Chemistry · 2005 · 152 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals

Ran Guan, Paul Tapang, Daniel Albert et al. · Cancer Research · 2005 · 146 citations

Life Sciences, Cancer Biology, Genetics +17

Phenoxyphenyl Sulfone<i>N</i>-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

Carol K. Wada, James H. Holms, Michael L. Curtin et al. · Journal of Medicinal Chemistry · 2001 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9